Trial Profile
A Phase I/II Trial of Multiple Dose VB-111 and Weekly Paclitaxel for the Treatment of Recurrent Platinum-Resistant Mullerian Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 27 Apr 2020
Price :
$35
*
At a glance
- Drugs Ofranergene obadenovec (Primary) ; Paclitaxel
- Indications Adenocarcinoma; Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Sarcoma; Uterine cancer
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors VBL Therapeutics
- 05 Apr 2020 Results assessing safety and efficacy of Treatment with VB-111 in combination with paclitaxel, published in the Gynecologic Oncology
- 04 Jun 2019 Results from 21 patients with recurrent platinum-resistant ovarian cancer presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 03 Jun 2019 Results presented in a VBL Therapeutics media release.